GlassScriptPhysician profile
Supritha A Shetty
NPI 1164410585
$6,999.77
in general payments reported to CMS, 2019-2025
42 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $203 · 2021: $79.37 · 2022: $1,128 · 2023: $1,660 · 2024: $1,425 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,643 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,642.96 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.02 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $1,129.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $1,119.96 | 2019-2025 | |
| Lilly USA, LLC | $613.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $334.30 | 2022-2025 | Freestyle Libre 3, Proclaim, Freestyle Libre 2 |
| Novo Nordisk INC | $270.12 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $247.91 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.07 | 2019-2025 | Jardiance, Tradjenta, Stiolto Respimat |
| Astellas Pharma US INC | $186.92 | 2019-2024 | Veozah, Myrbetriq |
| Bayer Healthcare Pharmaceuticals INC. | $184.92 | 2022-2025 | |
| Daiichi Sankyo INC. | $165.35 | 2020-2025 | Injectafer |
| Merck Sharp & Dohme LLC | $127.96 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Janssen Pharmaceuticals, INC | $115.69 | 2019-2020 | |
| Amgen INC. | $90.13 | 2019-2023 | Repatha, Otezla |
| Abiomed | $84.03 | 2023-2025 | Impella |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Supritha Shetty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.